Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.


Estrella Immunopharma Inc

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.18 Insider Own74.94% Shs Outstand36.38M Perf Week-0.77%
Market Cap46.93M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.12M Perf Month37.23%
Income-0.63M PEG- EPS next Q- Inst Own0.37% Short Float0.19% Perf Quarter18.89%
Sales0.00M P/S- EPS this Y- Inst Trans0.09% Short Ratio1.02 Perf Half Y0.78%
Book/sh0.23 P/B5.55 EPS next Y- ROA-2.28% Short Interest0.02M Perf Year-88.38%
Cash/sh0.13 P/C9.92 EPS next 5Y- ROE-2.51% 52W Range0.81 - 33.00 Perf YTD16.22%
Dividend Est.- P/FCF- EPS past 5Y- ROI-7.47% 52W High-96.09% Beta0.33
Dividend TTM- Quick Ratio62.34 Sales past 5Y- Gross Margin- 52W Low59.26% ATR (14)0.12
Dividend Ex-Date- Current Ratio62.34 EPS Y/Y TTM-44.10% Oper. Margin0.00% RSI (14)58.41 Volatility12.04% 10.82%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q51.47% Payout- Rel Volume2.01 Prev Close1.46
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume17.18K Price1.29
SMA2015.93% SMA5024.12% SMA200-1.29% Trades Volume34,514 Change-11.64%
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.